TY - JOUR TI - Danon disease: Further clinical and molecular heterogeneity AU - Sabourdy, F. AU - Michelakakis, H. AU - Anastasakis, A. AU - Garcia, V. AU - Mavridou, I. AU - Nieto, M. AU - Pons, M.-C. AU - Skiadas, C. AU - Moraitou, M. AU - Manta, P. AU - Elleder, M. AU - Levade, T. JO - Muscle and Nerve PY - 2009 VL - 39 TODO - 6 SP - 837-844 PB - SN - null TODO - 10.1002/mus.21252 TODO - alpha galactosidase; lysosome associated membrane protein 2; osteocalcin, article; cardiomyopathy; case report; child; controlled study; Danon disease; disease association; familial disease; gene mutation; genetic analysis; heart failure; human; human cell; human tissue; immunohistochemistry; male; muscle biopsy; priority journal; restriction mapping; skin fibroblast, alpha-Galactosidase; Amino Acid Substitution; Base Sequence; Cardiomyopathies; Cells, Cultured; Child; Child, Preschool; DNA Mutational Analysis; Exons; Female; Gene Deletion; Genetic Markers; Genetic Predisposition to Disease; Genotype; Glycogen Storage Disease Type IIb; Humans; Introns; Lysosome-Associated Membrane Glycoproteins; Male; Mutation; Pedigree TODO - Two families of Greek patients with subclinical to severe cardiomyopathy are presented. The diagnosis of Danon disease was supported by a total lack of LAMP2 immunostaining in cultured skin fibroblasts and muscle biopsies. The LAMP2 mutation carried by one patient (c.928G>A) has already been reported but with different symptoms. The second patient had a novel point deletion. This has not been described previously, but it could be detected easily by restriction analysis. This mutation was also found in the patient's brother, and it was associated with severe cardiomyopathy leading to heart failure. Surprisingly, the proband also had partial reduction of α-galactosidase A activity, despite the absence of characteristic clinical features of Fabry disease. A substitution in the GLA gene (c.937G>T) was found, and its involvement in the cardiac disease is discussed. © 2009 Wiley Periodicals, Inc. ER -